New Study Finds that Myeloma Can Be Detected by Simple Blood Tests
Patient Power: Diet Proves to Maintain Immune System for Myeloma Patients
Clinical Trial: New Inhibitor Tested for Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma Care Survivorship: The Need for Improvement
Mid-Year Myeloma Update with Paul Richardson, MD of the Dana Farber Cancer Institute
Dr. Paul Richardson shares a mid-year myeloma update to catch us up and provides a treatment overview
Tips for Joining Popular Multiple Myeloma Clinical Trials with Brian McMahon of SparkCures
Brian McMahon of SparkCures shares three steps patients can take to participate in clinical trials: awareness, understanding and action.
New Study Finds Potential Hazards of CRISPR Gene Editing
Former MLB All-Stars Dave Winfield and Steve Garvey Help Launch Myeloma MVP™
Dr. Eric Zhou: How to Overcome Sleep Problems After A Stem Cell Transplant
Researchers Discover Curcumin Impact in Fighting Myeloma But Note Limitations
Patient Power: Taking a Drug Holiday for Multiple Myeloma Patients
Certified Cancer Exercise Specialist Cathy Skinner's Advice to Myeloma Patients on Battling Fatigue
Myeloma Crowd Cycling: Richard Hite, Myeloma Survivor
Clinical Trial: New Monoclonal Antibody for Relapsed Multiple Myeloma (Lintuzumab + Actinium-225)
Clinical Trial: Phase 1 BCMA-CD3 Bispecific Antibody for Relapsed/Refractory Myeloma Patients
Changing Our Approach to Myeloma Care Changes Outcomes
Elotuzumab, Pomalyst and Dex Show Decreased Risk of Progression in Multiple Myeloma
Summer Is Officially Here… What’s the Best Way to Protect Yourself?
Stem Cell Transplant Still Improves Myeloma Patient Survival
EHA: INSIGHT Update on Multiple Myeloma
Raynaud's Disease and Myeloma… How to Cope
SparkCures Founder Brian McMahon Named One of "40 Under 40 in Cancer"
Legend Biotech and Janssen Partner on CAR T Cell Treatment for Multiple Myeloma
Overcoming Proteasome Inhibitor Resistance, Muhamed Baljevic, MD, University of Nebraska
Dr. Baljevic shares a clinical trial using cabozantinib with carfilzomib for patients who have become refractory (resistant) to carfilzomib.
